KVP Capital Advisors, LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001858198

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth Tilt how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 35 positions · Total reported value $122.33M · Top-10 concentration 58.3% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 18.4% · 3 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.4% · vs SPY -15.6% · Prev Value $136.24M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -2.0% · vs SPY -4.1% · Latest Value $122.33M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, KVP Capital Advisors, LP disclosed 35 equity positions with a combined reported value of $122.33M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 58.3% of reported value. HoldingsHub classifies the profile as Small / Health Tilt.

The largest disclosed positions as of Q3 2026 were PRAX ($12.49M), WHWK ($8.14M), SLN ($7.48M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, KVP Capital Advisors, LP opened 3 new positions, trimmed 1 and fully exited 3, a turnover rate of 18.4% of positions. The portfolio's overlap with the prior quarter was 84% of names.

The largest new positions opened in Q3 2026 were SLN ($7.48M), ADIL ($843.13K), DARE ($225.45K).

Of the 3 positions fully exited versus the prior quarter, the largest were AXSM ($2.94M), SRRK ($2.48M), VYNE ($325.71K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SLN SILENCE THERAPEUTICS PLC · $7.48M
  • ADIL ADIAL PHARMACEUTICALS INC · $843.13K
  • DARE YARROW BIOSCIENCE INC · $225.45K

Fully Exited (vs previous quarter)

  • AXSM AXSOME THERAPEUTICS INC. · prev qtr: $2.94M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $2.48M
  • VYNE YARROW BIOSCIENCES INC · prev qtr: $325.71K

Insider Transactions (Form 4)

Latest KVP Capital Advisors, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

KVP Capital Advisors, LP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 35 positions worth $122.33M in total. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).

Firm Snapshot

  • SEC registration: 801-136909 (status: Approved), registered 2026-08-20
  • Regulatory AUM (Form ADV): $123.05M as of 2026-06-29
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: kearnyvp.com

Portfolio Structure

  • 35 positions · $122.33M reported value (Q3 2026)
  • Top 10 holdings = 58.3% of reported value
  • Largest position: PRAX (PRAXIS PRECISION MEDICINES I) at 10.2%
  • Average position size: $3.50M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 1 reduced, 3 exited
  • 31 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintains a concentrated, healthcare-focused portfolio with modest adjustments, suggesting a bullish view on biotech/therapeutics but with selective trimming of some positions. No outright sells, indicating conviction in existing holdings. 2. Key moves: - Added: Silence Therapeutics (SLN) as a new position (6.11% weight). - Reduced: No explicit reductions (action field shows only "Hold" or "New"). Weight declines for PRAX, WHWK, ERAS, TRVI, and TNGX are due to price effects, not active sales. 3. Portfolio structure: Highly active, concentrated (35 positions, 10 holdings = 48.31% of AUM), with extreme bias toward Health Care (biotech/therapeutics). High-risk appetite, given volatile, pre-revenue companies. 4. Per-holding one-liner: - PRAX: Praxis Precision Medicines (cancer genomics). - WHWK: Whitehawk Therapeutics (RNA-targeted therapeutics). - SLN: Silence Therapeutics (RNA interference tech). - PTGX: Protagonist Therapeutics (inflammatory diseases). - MBX: MBX Biosciences (cell/gene therapy). - ERAS: Erasca (cancer therapeutics). - TRVI: Trevi Therapeutics (rare neurological diseases). - TNGX: Tango Therapeutics (cancer genomics). - EWTX: Edgewise Therapeutics (rare muscular diseases). - TNDM: Tandem Diabetes Care (insulin pumps). 5. Style summary: Biotech-focused fund with selective new bets and price-driven rebalancing, favoring clinical-stage therapeutics.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 06:05

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 42.90K $12.49M 10.21%
10.21%
Hold
2 2.17M $8.14M 6.66%
6.66%
Hold
3 684.12K $7.48M 6.11%
6.11%
New
4 53.00K $7.47M 6.10%
6.10%
Hold
5 121.52K $7.12M 5.82%
5.82%
Hold
6 455.00K $6.67M 5.45%
5.45%
Hold
7 414.00K $5.93M 4.85%
4.85%
Hold
8 230.26K $5.75M 4.70%
4.70%
Hold
9 133.00K $5.40M 4.41%
4.41%
Hold
10 301.00K $4.91M 4.01%
4.01%
Hold
11 462.36K $3.74M 3.06%
3.06%
Hold
12 226.57K $3.65M 2.98%
2.98%
Hold
13 28.50K $3.25M 2.66%
2.66%
Hold
14 605.28K $3.12M 2.55%
2.55%
Hold
15 102.00K $3.09M 2.52%
2.52%
Hold
16 79.70K $3.06M 2.50%
2.50%
Hold
17 43.75K $2.86M 2.34%
2.34%
Reduce
18 4.75K $2.57M 2.10%
2.10%
Hold
19 125.00K $2.57M 2.10%
2.10%
Hold
20 230.42K $2.40M 1.96%
1.96%
Hold
21 185.00K $2.33M 1.90%
1.90%
Hold
22 300.00K $2.30M 1.88%
1.88%
Hold
23 39.00K $2.30M 1.88%
1.88%
Hold
24 84.17K $2.12M 1.73%
1.73%
Hold
25 26.90K $1.63M 1.33%
1.33%
Hold
26 31.81K $1.58M 1.30%
1.30%
Hold
27 373.13K $1.55M 1.27%
1.27%
Hold
28 200.00K $1.42M 1.16%
1.16%
Hold
29 150.00K $1.20M 0.98%
0.98%
Hold
30 32.70K $1.06M 0.86%
0.86%
Hold
31 505.43K $970.43K 0.79%
0.79%
Hold
32 210.26K $843.13K 0.69%
0.69%
New
33 771.00K $801.84K 0.66%
0.66%
Hold
34 4.00K $318.08K 0.26%
0.26%
Hold
35 10.01K $225.45K 0.18%
0.18%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 90% R 90% F1 90% (modelled on 2026-Q2; 9/10 hit)

Historical Backtest (2 quarters)

Avg precision 80% · recall 80% · F1 80% · avg rank error 2.9 · Top-10 turnover 23%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 70% 70% 70% TERN · PRAX · WHWK · AXSM · PTGX · STRO · ERAS · TRVI · TNGX · INSM PRAX · WHWK · ERAS · TRVI · STRO · TNGX · MBX · PTGX · EWTX · TNDM
2026-Q3 ★ 90% 90% 90% PRAX · WHWK · ERAS · TRVI · STRO · TNGX · MBX · PTGX · EWTX · TNDM PRAX · WHWK · SLN · PTGX · MBX · ERAS · TRVI · TNGX · EWTX · TNDM

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings5 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-11.56%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+5.46%vs benchmark
Barra annualised vol45.5%Model estimate
Realised vol50.4%Annualised in window
Weighted beta0.75Raw exposure
Factor / specific risk45% / 55%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16KVP Capital Advisors, LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-11.56%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+5.46%Portfolio − benchmark
Arithmetic return sum-10.61%Difference vs compounded is the cross term
Weighted raw beta0.75Weighted holding betas
Realised volatility (annualised)50.40%Daily returns in window
Barra model volatility (annualised)45.53%Factor + specific
Factor share of variance44.9%Barra factors
Specific share of variance55.1%Stock residuals
Reported value$22.1M13F long US equity

2. Return attribution

The -10.61% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +1.28% 12.0%
Momentum & Growth 3 -7.27% -68.5%
Volatility & Tail Risk 7 +0.03% 0.3%
Industry 12 +6.98% 65.8%
Specific 1 -11.64% -109.6%
Return attribution (style + industry, %)-8.9-4.5+0.0+4.5+8.9Turnover+0.49Beta-0.52Max Drawdown-0.87Growth-0.92Amihud Illiquidity-1.01Non-linear Size+2.46Size+2.88Skewness-3.32Mid Cap-3.69Kurtosis+5.47Momentum-6.26Health Care+6.98Residual Volatility+7.49Historical Volatility-8.24
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.28 +3.29% +7.49% 70.6%
Health Care Industry +1.00 +6.98% +6.98% 65.8%
Kurtosis Style +0.73 +7.51% +5.47% 51.6%
Size Style -1.48 -1.95% +2.88% 27.1%
Non-linear Size Style +2.44 +1.01% +2.46% 23.2%
Turnover Style -0.10 -4.80% +0.49% 4.6%
Liquidity Style +0.41 +0.36% +0.15% 1.4%
Short-term Reversal Style -0.10 +0.87% -0.09% -0.8%
Beta Style -0.12 +4.44% -0.52% -4.9%
Max Drawdown Style +0.50 -1.76% -0.87% -8.2%
Growth Style -0.53 +1.75% -0.92% -8.6%
Amihud Illiquidity Style +2.27 -0.45% -1.01% -9.5%
Skewness Style +0.76 -4.39% -3.32% -31.3%
Mid Cap Style +1.91 -1.94% -3.69% -34.8%
Momentum Style +1.56 -4.00% -6.26% -59.0%
Historical Volatility Style +0.59 -14.00% -8.24% -77.7%
Specific Specific — — -11.64% -109.6%

3. Risk attribution

Annualised volatility is 45.53%; factor risk explains 44.9% of variance and specific risk 55.1%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-59.6-29.8+0.0+29.8+59.6Beta-0.37Max Drawdown+0.36Growth+0.37Liquidity+0.40Skewness+1.00Historical Volatility+2.44Non-linear Size+2.50Amihud Illiquidity+2.81Size+4.62Mid Cap+6.06Momentum+6.62Residual Volatility+7.09Health Care+10.55Specific+55.15
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 55.1% +25.11% 25.1%
Health Care Industry +1.00 10.6% +4.80% 4.8%
Residual Volatility Style +2.28 7.1% +3.23% 3.2%
Momentum Style +1.56 6.6% +3.02% 3.0%
Mid Cap Style +1.91 6.1% +2.76% 2.8%
Size Style -1.48 4.6% +2.10% 2.1%
Amihud Illiquidity Style +2.27 2.8% +1.28% 1.3%
Non-linear Size Style +2.44 2.5% +1.14% 1.1%
Historical Volatility Style +0.59 2.4% +1.11% 1.1%
Skewness Style +0.76 1.0% +0.45% 0.5%
Liquidity Style +0.41 0.4% +0.18% 0.2%
Growth Style -0.53 0.4% +0.17% 0.2%
Max Drawdown Style +0.50 0.4% +0.17% 0.2%
Kurtosis Style +0.73 0.2% +0.10% 0.1%
Beta Style -0.12 -0.4% -0.17% -0.2%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.9-0.70.51.72.8Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -1.48 +2.10 -3.58
Non-linear Size +2.44 +1.68 +0.77
Mid Cap +1.91 +0.13 +1.78
Beta -0.12 +1.29 -1.41
Momentum +1.56 +0.72 +0.85
Short-term Reversal -0.10 -0.64 +0.54
Residual Volatility +2.28 -0.40 +2.68
Historical Volatility +0.59 +0.86 -0.27
Liquidity +0.41 +0.11 +0.30
Amihud Illiquidity +2.27 +1.16 +1.12
Turnover -0.10 +0.21 -0.31
Growth -0.53 +0.58 -1.11
Leverage (Downside Vol) -0.01 +0.14 -0.15
Skewness +0.76 +0.24 +0.52
Kurtosis +0.73 +0.21 +0.51
Max Drawdown +0.49 -0.08 +0.58

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -11.17% +8.29% +24.98% -0.34% -19.12% -11.32%
Total +23.98% +15.50% -34.97% +4.52%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
PTGX PROTAGONIST THERAPEUTICS INC Health Care 33.75% -11.40% -3.85% Hold
TNGX TANGO THERAPEUTICS INC Health Care 25.96% -3.13% -0.81% Hold
INSM INSMED INC Health Care 14.70% +7.66% +1.13% Hold
AVBP ARRIVENT BIOPHARMA INC Health Care 13.96% -61.82% -8.63% Hold
UTHR UNITED THERAPEUTICS CORP DEL Health Care 11.63% +8.49% +0.99% Hold
Contribution rank Symbol Sector Weight Return Contribution
1 INSM Health Care 14.70% +7.66% +1.13%
2 UTHR Health Care 11.63% +8.49% +0.99%
3 TNGX Health Care 25.96% -3.13% -0.81%
4 PTGX Health Care 33.75% -11.40% -3.85%
5 AVBP Health Care 13.96% -61.82% -8.63%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -11.56%, versus -17.01% for the QQQ synthetic benchmark — an excess of +5.46%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +7.49%, Health Care +6.98%, Kurtosis +5.47%; the largest drags came from Historical Volatility -8.24%, Momentum -6.26%, Mid Cap -3.69%. Specific (stock-level) return contributed -11.64%.
  3. Risk attribution: Barra model volatility is 45.53% annualised; factor risk explains 45% of variance and specific risk 55%. The largest factor risk sources are Health Care 10.6%, Residual Volatility 7.1%, Momentum 6.6%.
  4. Style tilt: size -1.48, momentum +1.56, volatility +0.59, liquidity +0.41; the weighted raw beta is 0.75. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.50% and interaction -34.97%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did KVP Capital Advisors, LP buy in 2026-Q3?

In its 2026-Q3 13F filing, KVP Capital Advisors, LP reported 35 equity positions worth $122.33M in aggregate; its largest disclosed positions were PRAX ($12.49M), WHWK ($8.14M), SLN ($7.48M).

How large is KVP Capital Advisors, LP's portfolio?

KVP Capital Advisors, LP reported $122.33M of long equity holdings across 35 positions as of 2026-Q3. Top-10 holdings account for 58.3% of reported value.

What is KVP Capital Advisors, LP's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/kvp-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →